594 Dose Escalation of Next Generation Anti-Ctla-4 Antibody ONC-392 in Combination with Fixed Dose of Pembrolizumab in Patients with Advanced Solid Tumors
Regular and Young Investigator Award Abstracts（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined